SCHEMBL140140

SCHEMBL140140

CCC(C)CCNC(C)C(O)(P(=O)(O)O)P(=O)(O)O

nearest known ligand 0.39

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
FDPS P14324 3/20 0.39
MMP1 P03956 1/20 0.31
MMP2 P08253 1/20 0.31
MMP3 P08254 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6045245 0.71 FDPS (0.46) FDPS
SCHEMBL7151614 0.68 MMP1 (0.30) MMP1MMP2MMP3
SCHEMBL140141 0.67 FDPS (0.38) FDPS
SCHEMBL8048681 0.67 FDPS (0.40) FDPS
SCHEMBL7952391 0.66
SCHEMBL23902088 0.66 CYP2D6 (0.30)
SCHEMBL18868458 0.66 CYP2D6 (0.30)
SCHEMBL15694717 0.64 ACE2 (0.39)
SCHEMBL23058665 0.64 ALDH1A1 (0.32)
SCHEMBL16229978 0.64 ALDH1A1 (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1233770-B1 PHOSPHONATE COMPOUNDS UNIV CALIFORNIA AT SAN DIEGO (US) 2008-02-13 EP claimed
US-6696427-B1 ADMINISTERING PHOSPHORUS COMPOUNDS SUCH AS AMINO-HYDROXY-METHYLIDENE-BISPHOSPHONIC ACID, TO DEACTIVATE LYMPHOCYTES AND AS VIRICIDES, BACTERICIDES, FUNGICIDES OR PARASITICIDES JOMAA PHARMAKA GMBH (DE) 2004-02-24 US claimed
EP-1140113-B1 USE OF BISPHOSPHONATES FOR THE PREVENTION AND TREATMENT OF INFECTIOUS PROCESSES BIOAGENCY AG (DE) 2003-11-05 EP claimed
US-10071110-B2 Phosphonate compounds THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2018-09-11 US disclosed
US-20170239279-A1 PHOSPHONATE COMPOUNDS UNIV CALIFORNIA (US) 2017-08-24 US disclosed
US-9649321-B2 Phosphonate compounds THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-05-16 US disclosed
US-20160067268-A1 PHOSPHONATE COMPOUNDS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-03-10 US disclosed
US-9206208-B2 Phosphonate compounds THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2015-12-08 US disclosed
US-20150141375-A1 Methods of Treating Viral Associated Diseases CHIMERIX, INC. 2015-05-21 US disclosed
US-8889658-B2 Phosphonate compounds THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-11-18 US disclosed
US-8710030-B2 Phosphonate compounds THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-04-29 US disclosed
US-20050182019-A1 An antiviral nucleoside in which the 5'-hydroxyl group has been substituted for a phosphonate or methyl phosphonate that is covalently linked to an alkylethanediol; osteoporosis; anticarcinogenic agents; viricides THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2005-08-18 US disclosed
US-20050176673-A1 guanin-9-yl, adenin-9-yl, 2,6-diaminopurin-9-yl, 2-aminopurin-9-yl or their 1-deaza, 3-deaza, or 8-aza compounds, or cytosin-1-yl - ethoxymethanephosphonic acid derivatives, used to treat osteoporosis and other disorders of bone metabolism, cancer, or viral infections THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2005-08-11 US disclosed
US-20040127735-A1 New phosphonate ester derivatives of drugs such as antivirals cidofovir, adefovir, tenofovir, azidothymidine (AZT), or bisphosphonates such as alendronate, or anticancers such as cytosine arabinoside; side effect reduction, less toxic; antiviral THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2004-07-01 US disclosed
US-6716825-B2 OSTEOPOROSIS AND OTHER DISORDERS OF BONE METABOLISUM, CANCER, VIRAL INFECTIONS, AND THE LIKE. THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2004-04-06 US disclosed
US-6696427-B1 ADMINISTERING PHOSPHORUS COMPOUNDS SUCH AS AMINO-HYDROXY-METHYLIDENE-BISPHOSPHONIC ACID, TO DEACTIVATE LYMPHOCYTES AND AS VIRICIDES, BACTERICIDES, FUNGICIDES OR PARASITICIDES JOMAA PHARMAKA GMBH (DE) 2004-02-24 US disclosed
US-20040019232-A1 Analogs of phosphonate and bisphosphonate compounds based on bone resorption suppressors (alendronic acid), viricides (cidofovir) and antineoplastic agents (bemcitabine); nontoxic; bioavailability; side effects reduction NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2004-01-29 US disclosed
EP-1140113-B1 USE OF BISPHOSPHONATES FOR THE PREVENTION AND TREATMENT OF INFECTIOUS PROCESSES BIOAGENCY AG (DE) 2003-11-05 EP disclosed
EP-1089761-B1 MEDICAMENTS CONTAINING BISPHOSPHONIC ACIDS AND DERIVATIVES THEREOF WHICH ARE PROVIDED FOR PREVENTING AND TREATING AUTOIMMUNE DISEASES AND ALLERGIES JOMAA HASSAN (DE) 2002-09-25 EP disclosed
EP-0563096-B1 NOVEL METHYLENEBISPHOSPHONIC ACID DERIVATIVES LEIRAS OY (FI) 2000-05-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050176673-A1 guanin-9-yl, adenin-9-yl, 2,6-diaminopurin-9-yl, 2-aminopurin-9-yl or their 1-deaza, 3-deaza, or 8-aza compounds, or cytosin-1-yl - ethoxymethanephosphonic acid derivatives, used to treat osteoporosis and other disorders of bone metabolism, cancer, or viral infections ENPP1, ADA, ENTPD5 FDPS 1302/4885MMP1 4184/4885MMP2 4610/4885
US-10071110-B2 Phosphonate compounds PHPT1, PHOSPHO1, PIK3CA FDPS 115/4885MMP1 4542/4885MMP2 4511/4885
US-20040127735-A1 New phosphonate ester derivatives of drugs such as antivirals cidofovir, adefovir, tenofovir, azidothymidine (AZT), or bisphosphonates such as alendronate, or anticancers such as cytosine arabinoside; side effect reduction, less toxic; antiviral TYMP, ADA, DCTD FDPS 251/4885MMP1 4191/4885MMP2 4703/4885
US-20040019232-A1 Analogs of phosphonate and bisphosphonate compounds based on bone resorption suppressors (alendronic acid), viricides (cidofovir) and antineoplastic agents (bemcitabine); nontoxic; bioavailability; side effects reduction BPGM, PPA1, INPP5D FDPS 360/4885MMP1 2781/4885MMP2 4203/4885
US-20170239279-A1 PHOSPHONATE COMPOUNDS PHPT1, PHOSPHO1, PIK3CA FDPS 115/4885MMP1 4542/4885MMP2 4511/4885
US-20160067268-A1 PHOSPHONATE COMPOUNDS PHPT1, PHOSPHO1, PIK3CA FDPS 115/4885MMP1 4542/4885MMP2 4511/4885
US-20050182019-A1 An antiviral nucleoside in which the 5'-hydroxyl group has been substituted for a phosphonate or methyl phosphonate that is covalently linked to an alkylethanediol; osteoporosis; anticarcinogenic agents; viricides MTAP, SAMHD1, NT5C3B FDPS 1276/4885MMP1 2187/4885MMP2 2532/4885
US-20150141375-A1 Methods of Treating Viral Associated Diseases HAVCR2, EIF2AK2, TSLP FDPS 506/4885MMP1 708/4885MMP2 1690/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.